CCL2 and Parkinson disease: Specifically, increased CSF levels of ICAM-1, IL-8, MCP-1, and MIP-1 beta were associated with decreased scores of mild cognitive impairment and higher CSF levels of neurodegenerative/PD-specific biomarkers in the total PD cohort.